Johnson & Johnson
$262.51Change from previous close: −0.84%Absolute change: −$2.23
Latest news
- Johnson & Johnson vs. Eli Lilly: Which Pharma Stock Can Make Your Portfolio Healthier in 2026? (opens in a new tab)
- Bristol-Myers Squibb vs. Johnson & Johnson: Comparing Quarterly Revenue Scale (opens in a new tab)
- Johnson & Johnson (NYSE:JNJ) Raises Its Payout (opens in a new tab)
- Johnson & Johnson survey finds women not connecting menopause to eye health changes (opens in a new tab)
- History Says Johnson & Johnson Beats Medtronic. Here's Why I'd Still Consider MDT for the Next Decade. (opens in a new tab)
- New Global Survey by Johnson & Johnson Finds Most Women Don’t Connect Eye Health Changes with Menopause (opens in a new tab)
- New Global Survey by Johnson & Johnson Finds Most Women Don't Connect Eye Health Changes with Menopause (opens in a new tab)
- 5 High-Yield Dividend Stocks That Pass the Coverage Test (Not Just the Yield Test) (opens in a new tab)
- ABBV Stock Rises 25% in 6 Months: Time to Buy, Hold or Sell? (opens in a new tab)
- Johnson & Johnson (JNJ) Stock Could Be Undervalued On Future Cash Flow (opens in a new tab)
- What is Johnson & Johnson’s (JNJ) Economic Moat, and is it Widening or Narrowing? (opens in a new tab)
- 3 Reasons Johnson & Johnson Is Still a Buy With Its Stock Near a Record High (opens in a new tab)
- Was The Run In JNJ Stock Hiding In Plain Sight? (opens in a new tab)
- Microsoft vs. Johnson & Johnson: Which Dividend Will Pay You More in 10 Years? (opens in a new tab)
- Are You Overpaying For Pfizer Stock Versus Its Rivals? (opens in a new tab)
- Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now (opens in a new tab)
- What Is Merck Stock's Biggest Opportunity? (opens in a new tab)
- BofA Boosts AbbVie and J&J Price Targets on Growth and Pipeline Strength (opens in a new tab)
- SCHD's Top Sector Bet Is Healthcare at 20.7%. I'm Not Sure What's More Surprising: What It Doesn't Hold, or What It Does. (opens in a new tab)
- Johnson & Johnson Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Acc (opens in a new tab)
- What Does Johnson & Johnson (JNJ) Long Term IMAAVY Data Mean For gMG? (opens in a new tab)
- Johnson & Johnson (JNJ) Shares In Focus After New Adolescent gMG Data (opens in a new tab)
- Johnson & Johnson (JNJ) Sees a More Significant Dip Than Broader Market: Some Facts to Know (opens in a new tab)
- Do You Really Understand ISRG Stock's Risk? (opens in a new tab)
- Muse AI Agent Stock Portfolio: 2 Non-AI Stock Picks You Should Not Miss (opens in a new tab)
- Defensive Dividends: 3 Companies Investors Can Rely On (opens in a new tab)
- Is Eli Lilly Stock a Good Fit For Your Portfolio Risk? (opens in a new tab)
- Johnson & Johnson's psoriasis drug Icotyde could hit $4.5B in peak sales, BofA says (opens in a new tab)
- Johnson & Johnson Q3 Preview: Analyst Projects In-Line Sales, Earnings Miss (opens in a new tab)
- Johnson & Johnson Reports IMAAVY Myasthenia Gravis Data (opens in a new tab)